Literature DB >> 18408106

Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease.

Daniel El Fassi, Claus H Nielsen, Jens Kjeldsen, Ole Clemmensen, Laszlo Hegedüs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18408106     DOI： 10.1136/gut.2007.138305

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  44 in total

Review 1.  Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab.

Authors:  Laszlo Hegedüs; Terry J Smith; Raymond S Douglas; Claus H Nielsen
Journal:  Clin Endocrinol (Oxf)       Date:  2011-01       Impact factor: 3.478

Review 2.  Crohn disease: a current perspective on genetics, autophagy and immunity.

Authors:  Thaddeus S Stappenbeck; John D Rioux; Atsushi Mizoguchi; Tatsuya Saitoh; Alan Huett; Arlette Darfeuille-Michaud; Tom Wileman; Noboru Mizushima; Simon Carding; Shizuo Akira; Miles Parkes; Ramnik J Xavier
Journal:  Autophagy       Date:  2011-04-01       Impact factor: 16.016

Review 3.  Animal models of IBD: linkage to human disease.

Authors:  Atsushi Mizoguchi; Emiko Mizoguchi
Journal:  Curr Opin Pharmacol       Date:  2010-06-08       Impact factor: 5.547

4.  IL-10-producing regulatory B10 cells inhibit intestinal injury in a mouse model.

Authors:  Koichi Yanaba; Ayumi Yoshizaki; Yoshihide Asano; Takafumi Kadono; Thomas F Tedder; Shinichi Sato
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

5.  Peritoneal cavity regulatory B cells (B10 cells) modulate IFN-γ+CD4+ T cell numbers during colitis development in mice.

Authors:  Damian Maseda; Kathleen M Candando; Susan H Smith; Ioannis Kalampokis; Casey T Weaver; Scott E Plevy; Jonathan C Poe; Thomas F Tedder
Journal:  J Immunol       Date:  2013-08-05       Impact factor: 5.422

6.  A novel IL-10-independent regulatory role for B cells in suppressing autoimmunity by maintenance of regulatory T cells via GITR ligand.

Authors:  Avijit Ray; Sreemanti Basu; Calvin B Williams; Nita H Salzman; Bonnie N Dittel
Journal:  J Immunol       Date:  2012-02-24       Impact factor: 5.422

7.  Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges.

Authors:  Klaus Lehmann-Horn; Helena C Kronsbein; Martin S Weber
Journal:  Ther Adv Neurol Disord       Date:  2013-05       Impact factor: 6.570

Review 8.  Rituximab in the Treatment of Thyroid Eye Disease: A Review.

Authors:  Rochella A Ostrowski; Melissa R Bussey; Yasmin Shayesteh; Walter M Jay
Journal:  Neuroophthalmology       Date:  2015-06-17

9.  Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.

Authors:  Mario Salvi; Guia Vannucchi; Nicola Currò; Irene Campi; Danila Covelli; Davide Dazzi; Simona Simonetta; Claudio Guastella; Lorenzo Pignataro; Sabrina Avignone; Paolo Beck-Peccoz
Journal:  J Clin Endocrinol Metab       Date:  2014-12-15       Impact factor: 5.958

Review 10.  The current state of the art for biological therapies and new small molecules in inflammatory bowel disease.

Authors:  Sudarshan Paramsothy; Adam K Rosenstein; Saurabh Mehandru; Jean-Frederic Colombel
Journal:  Mucosal Immunol       Date:  2018-06-15       Impact factor: 7.313
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.